OUR SCIENCE
A rare blood cancer.
A targeted answer.
Taran is taking a targeted approach to a disease with no FDA-approved therapies.
We are developing therapies for myeloid blood cancers and immune-driven diseases, with a focus on Chronic myelomonocytic leukemia (CMML). CMML is an hematologic neoplasm characterized by sustained peripheral blood monocytosis with a median overall survival of 28 to 32 months. There are currently no FDA-approved disease-modifying therapies for CMML.
We aim to fix this.
PRIMARY CLINICAL PHASE PROGRAM
LENZILUMAB
(LENZ)
LENZ is an investigational biologic agent that improves the clinical parameters in patients with CMML.
What it targets: Soluble human GM-CSF, a signaling protein that drives abnormal myeloid cell survival and growth.
How it works: LENZ is a high-affinity engineered monoclonal antibody that binds and neutralizes GM-CSF before it can activate the signaling pathway abnormal cells depend on to survive and multiply. Reducing that signal removes a key survival advantage of the malignant cells.
GM-CSF-driven signaling is present in an estimated 90% of proliferative CMML cases, giving LENZ a mechanistic rationale tied directly to this disease's biology rather than a general cytotoxic effect. It also works through a different pathway than azacitidine, the chemotherapy standard of care (SOC), which supports using the two together rather than as competing options.
What's distinctive: LENZ, combined with azacitidine, has produced meaningfully higher response rates than azacitidine alone. There is also molecular evidence that treatment is suppressing the specific mutations driving the disease.
Event Free Survival Difference
LENZ combined with azacitidine has demonstrated encouraging clinical outcomes, offering new potential for patients with CMML.
Descriptive context only. Eligibility, endpoints, event definitions and follow-up differ across these three studies.
1
2
Drummond, et al. (2014). Leukemia, 28(7), 1570–1572.
3
Itzykson, et al. (2023). Journal of Clinical Oncology, 41(10), 1888–1897.
Hiwase, et al. (2025). Blood, 146 (Supplement 1)
The Progress
Across a range of conditions
Multiple Inflammatory & Immunological Conditions
9
Studies
700+
Patients
CMML
Phase 3 Ready
~80%
Overall Response Rate
~4x
Improvement on SoC
0.28
Hazard Ratio
SECONDARY PRECLINICAL PROGRAM
IFABOTUZUMAB
(IFAB)
What it targets: EphA3, a receptor tyrosine kinase largely inactive in healthy adult tissue but reactivated on tumor cells, tumor blood vessels, tumor-supportive tissue, and fibrotic tissue.
How it works: IFAB is an engineered monoclonal antibody designed to kill tumor cells, recruit immune cells, disrupt tumor blood vessels, and interfere with surrounding survival signals.
What's distinctive: Early clinical studies have reported objective responses and reversal of bone marrow fibrosis in blood cancers, alongside specific tumor imaging, favorable safety findings, and sustained disease stabilization in glioblastoma. Preclinical pancreatic cancer research also suggests potential to enhance chemotherapy and immunotherapy.
IFAB has been studied in 75+ patients across blood cancers and glioblastoma. Taran is exploring its potential in additional solid tumors and fibrotic disease.
PATIENT RESOURCES
For Patients
We are committed to helping patients as we develop therapies for myeloid disorders. Every member of our team is here to support and provide patients, families, and caregivers with the resources they need as they navigate through this journey.
OUR RESEARCH
Publications & Presentations
Secondary Acute Myeloid Leukemia
transformed from chronic myelomonocytic leukemia
is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy
Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement
Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years
